CLICK HERE TO FIND OUT MORE
IMMUNO-ONCOLOGY SUMMIT EUROPE
19th-23rd March 2018
Cambridge Healthtech Institute’s Third Annual Immuno-Oncology Summit Europe returns to the heart of London’s Canary Wharf for a full week of cutting-edge science and discussion. Through three back-to-back conference tracks, delegates will hear from the research teams at the forefront of the rapidly developing field of cancer biotherapeutics.
- ImmTAC® Reagents: Novel Bi-Functional TCR-Based Biologics for Targeted Immunotherapy
- Bent Jakobsen, PhD, CSO, Immunocore
- Anti-Tumor Antibody Effector Contributions to Synergistic Innate and Adaptive Immunity
- K. Dane Wittrup, PhD, Carbon P. Dubbs Professor, Chemical Engineering and Biological Engineering, Massachusetts Institute of Technology
- PD-1 Antibody Is a Broad Spectrum Anticancer Therapy Both as Monotherapy and in Combination
- Roy D. Baynes, MD, PhD, Senior Vice President & Head, Global Clinical, Development, CMO, Merck, Sharpe & Dohme
3 FOCUSED CONFERENCE PROGRAMS
- In Adoptive T-Cell Therapy, leaders in the field from academia, industry and the clinic present advances in TCRs, CAR-Ts, TILs, and “unconventional” T cells. Investigators focus on increasing the range of potential targets, overcoming immune evasion mechanisms, affinity optimization, enhancement of efficacy, avoidance of tox and alloreactive occurrences, and on advancing T cell stimulation and T cell homing.
- In Combination Immunotherapy, investigators are applying knowledge of the tumour environment by developing new combination approaches with new modes of action. In this track, attendees will discover how investigators are improving on the limitations of monotherapies with the application of clever combination strategies.
- Immunomodulatory Antibodies examines the mechanisms behind checkpoint inhibition and presents advances with checkpoint blockers, agonists, CD3 targeting bispecifics and with targeting Fc receptors. It presents novel approaches to overcome resistance and boost the immune-stimulatory response as well as means of limiting toxicity, PK issues and auto-immune side effects.
“The breadth and depth of the presentations were outstanding and resulted in many interesting conversations and contacts. This is what makes or breaks an event at the end of the day. The event, logistics and location were faultless too.”
– Senior Scientific Investigator, Systems Modeling and Translational Biology, GlaxoSmithKline
“Congratulations on organizing such a great event. I very much enjoyed the talks. The event was intimate enough to allow for the interactions you don’t get with larger formal conferences.”
– Research Scientist, Autolus
“Incredible lineup of the brightest minds in immuno-oncology.”
– Senior Scientist, Immunotherapy Stanford University School of Medicine
CLICK HERE TO FIND OUT MORE